Lifesci Capital Equities Analysts Decrease Earnings Estimates for ALX Oncology Holdings Inc. (NASDAQ:ALXO)

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Analysts at Lifesci Capital decreased their Q2 2024 EPS estimates for ALX Oncology in a research note issued to investors on Wednesday, July 31st. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($0.75) per share for the quarter, down from their previous forecast of ($0.69). Lifesci Capital has a “Hold” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.89) per share. Lifesci Capital also issued estimates for ALX Oncology’s Q3 2024 earnings at ($0.78) EPS, Q4 2024 earnings at ($0.75) EPS and FY2024 earnings at ($3.00) EPS.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.16.

A number of other research analysts have also commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Wednesday, May 29th. Stifel Nicolaus cut their target price on shares of ALX Oncology from $14.00 to $5.00 and set a “hold” rating for the company in a research note on Thursday, August 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.17.

ALX Oncology Stock Up 0.7 %

ALXO opened at $2.75 on Monday. The business has a 50 day moving average price of $6.84 and a 200 day moving average price of $11.66. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.21 and a current ratio of 5.21. ALX Oncology has a twelve month low of $2.50 and a twelve month high of $17.83. The firm has a market cap of $143.28 million, a P/E ratio of -0.74 and a beta of 1.06.

Insider Buying and Selling at ALX Oncology

In related news, insider Jaume Pons sold 20,000 shares of the stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $8.43, for a total value of $168,600.00. Following the completion of the transaction, the insider now owns 604,205 shares of the company’s stock, valued at $5,093,448.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Sophia Randolph sold 12,000 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $15.94, for a total value of $191,280.00. Following the sale, the insider now owns 330,349 shares in the company, valued at approximately $5,265,763.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jaume Pons sold 20,000 shares of the stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $8.43, for a total transaction of $168,600.00. Following the sale, the insider now owns 604,205 shares of the company’s stock, valued at approximately $5,093,448.15. The disclosure for this sale can be found here. Insiders have sold 58,469 shares of company stock valued at $554,946 in the last 90 days. 33.40% of the stock is currently owned by company insiders.

Institutional Trading of ALX Oncology

Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its position in ALX Oncology by 445.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after acquiring an additional 4,706 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of ALX Oncology in the fourth quarter valued at $28,000. abrdn plc bought a new position in shares of ALX Oncology in the fourth quarter valued at about $986,000. Jump Financial LLC acquired a new position in ALX Oncology during the 4th quarter worth about $371,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in ALX Oncology during the 4th quarter worth about $215,000. 97.97% of the stock is owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.